Trump Team Outlines Healthcare Agenda—No Mention of Drug Prices
Xconomy
NOVEMBER 10, 2016
There is no mention of drug pricing or what the administration might do about frequent price increases, such as Mylan’s EpiPen practice, that critics say are unsubstantiated and unethical. People will also be able to purchase insurance across state lines, even though the states will be in charge of regulating their markets.
106 
Let's personalize your content